Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
| 対象疾患 | Relapsing-remitting Multiple Sclerosis |
|---|---|
| 相 | 第1相 |
| スポンサー | Cellerys AG |
| ステータス | 完了 |
| 参加者数 | 11 名 |
| 介入（薬剤） | CLS12311 low, CLS12311 medium, CLS12311 high, uncoupled RBCs |
| 開始日 | 2024年6月18日 |
| 完了日 | 2025年12月23日 |
| 結果公開日 | 2026年6月8日 |
概要
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS). CLS12311 consists of autologous red blood cells (RBCs) coupled with antigenic peptides and aims to treat RRMS by induction of antigen-specific immune tolerance.
Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety of CLS12311]
| CLS12311 Low | 5 events |
|---|---|
| CLS12311 Medium | 28 events |
| CLS12311 High | 16 events |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
- A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
- Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche